Tuesday, October 1, 2024
HomeIndustries

Industries

Leap Therapeutics to Present Positive New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab

Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, announced the Company will be presenting updated data from the DisTinGuish...

Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022

Exelixis, Inc. (Nasdaq: EXEL) today announced results for cabozantinib (CABOMETYX®) in combination with immunotherapies in patients with advanced colorectal cancer, including encouraging data from...

ImmVira’s MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data

ImmVira's breakthrough product MVR-T3011 IV, global first clinical-stage oncolytic herpes simplex virus (oHSV) via intravenous injection, has recently completed first 2 cohorts dose-escalation of...

i2c Selected by Leading Payments Innovators Across Latin America, Caribbean

i2c Inc., a leading provider of digital payment and banking technology, announced that the company has been selected to power payment programs across nine...

ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial

ImmunityBio, Inc, a clinical-stage immunotherapy company, announced interim results (N=63) in its metastatic pancreatic cancer trial (QUILT 88) showing that the overall survival rate...
0FansLike
0FollowersFollow
spot_img

Hot Topics